This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| NCI Cancer Trials Support Unit | |
|---|---|
| Name | Cancer Trials Support Unit |
| Formation | 2000s |
| Headquarters | Bethesda, Maryland |
| Parent organization | National Cancer Institute |
NCI Cancer Trials Support Unit
The NCI Cancer Trials Support Unit (CTSU) is a centralized operational service created to streamline clinical trial activation, site enrollment, data exchange, and regulatory coordination for federally funded oncology trials. It supports cooperative groups, academic medical centers, and community hospitals in executing multicenter studies and connects trial networks with pharmaceutical sponsors, clinical investigators, and regulatory bodies. The unit emphasizes standardized processes for trial initiation, quality assurance, and electronic data interchange to accelerate translational research and improve patient access.
CTSU functions as an operational backbone linking National Cancer Institute programs with cooperative oncology networks such as Cancer and Leukemia Group B, North Central Cancer Treatment Group, Southwest Oncology Group, RTOG and other trial consortia. It interacts with major research institutions including Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, Dana-Farber Cancer Institute, and community-oriented centers participating through networks like NCI Community Oncology Research Program. CTSU coordinates among regulatory authorities including the Food and Drug Administration and funding agencies such as the National Institutes of Health. The unit supports trial logistics that involve contract research organizations, biopharmaceutical sponsors like Pfizer, Roche, and Merck, and patient advocacy organizations including American Cancer Society and Susan G. Komen.
CTSU emerged in the context of reforms following cooperative group restructuring in the early 2000s and initiatives connected to the Cancer Moonshot vision and broader National Institutes of Health modernization efforts. Its formation responded to recommendations from panels convened by entities such as the Institute of Medicine and advisory committees associated with National Cancer Institute. Early development engaged cooperative groups including Children's Oncology Group and infrastructure contributions from academic centers like University of California, San Francisco and Stanford University. Subsequent milestones involved integration with electronic systems promoted by the Office of Management and Budget and harmonization with international trial standards advocated by organizations such as the World Health Organization.
CTSU operates under the administrative auspices of the Division of Cancer Treatment and Diagnosis within the National Cancer Institute, reporting through program directors and governance bodies that include representatives from cooperative groups, academic health centers, and community partners. Oversight and policy guidance involve stakeholders from Department of Health and Human Services committees, protocol steering committees drawn from institutions like University of Texas MD Anderson Cancer Center and Cleveland Clinic, and regulatory liaisons with the Food and Drug Administration. Advisory input has come from panels containing members with appointments at institutions such as Yale School of Medicine, Columbia University Irving Medical Center, and University of Pennsylvania.
CTSU provides centralized services including protocol registration, credentialing for investigative sites, investigational agent distribution coordination, and trial initiation support used by networks such as ECOG-ACRIN and Alliance for Clinical Trials in Oncology. It administers electronic systems for eligibility screening, supports institutional review board interactions with local IRBs like those at Harvard Medical School and University of Chicago, and facilitates contracting processes with legal offices at centers including Northwestern University and University of Michigan. The unit also manages biospecimen shipping logistics used by repositories such as National Biospecimen Network-aligned banks and collaborates with laboratory partners like Broad Institute for correlative science.
Operational workflows supported by CTSU include protocol activation pipelines used by cooperative groups such as RTOG and SWOG, central Institutional Review Board reliance mechanisms, and site performance monitoring frameworks implemented in collaboration with centers like Fred Hutchinson Cancer Research Center. The unit standardizes case report forms, adverse event reporting consistent with Common Terminology Criteria for Adverse Events usage at institutions like Memorial Sloan Kettering Cancer Center, and coordinates drug accountability across wholesalers and pharmacies affiliated with University Hospital systems. Training and certification for research staff often involve partnerships with educational programs at Duke University School of Medicine and University of North Carolina at Chapel Hill.
CTSU implements electronic data capture, data transfer agreements, and interoperability standards aligning with systems used by ClinicalTrials.gov registrants and research IT platforms at institutions such as Yale-New Haven Hospital and Brigham and Women's Hospital. It integrates with centralized data management platforms promoted by the National Cancer Informatics Program and supports biostatistical collaborations with groups at Fred Hutchinson and Mayo Clinic Cancer Center. Data security and privacy practices align with policies from Department of Health and Human Services offices and technical frameworks championed by National Institute of Standards and Technology.
CTSU maintains partnerships with cooperative groups including Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and Children's Oncology Group, and engages industry partners such as AstraZeneca and Bristol Myers Squibb for trial sponsorship. It collaborates with academic consortia at University of California system campuses, regional networks like NCORP, and philanthropic funders including Bill & Melinda Gates Foundation for capacity-building. International interactions include coordination with networks in Europe and Asia, engaging organizations like European Organisation for Research and Treatment of Cancer and national cancer centers such as National Cancer Center Hospital (Japan).
Evaluations of CTSU assess metrics such as trial activation time, accrual rates at sites including community hospitals participating via NCORP, data quality benchmarks used by biostatistics cores at Dana-Farber and outcome measures informing policy at National Cancer Institute. Impact analyses reference publications in journals where investigators at Johns Hopkins, Memorial Sloan Kettering, and MD Anderson report multicenter trial outcomes. Continuous improvement efforts reflect recommendations from panels including members from Institute of Medicine and stakeholder input from advocacy groups like Leukemia & Lymphoma Society.
Category:Cancer research organizations